Adomeglivant
Title | Journal |
---|---|
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. | Diabetes care 20160701 |
Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. | Diabetes, obesity & metabolism 20150401 |